Do analysts rate GNTA or IMMP?

Prima BioMed has a consensus target price of $5.50, indicating a potential upside of 1,257.69%. Given Prima BioMed's stronger consensus rating and higher possible upside, analysts plainly believe Prima BioMed is more favorable than Genenta Science. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Genenta Science 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Prima BioMed 1 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.75

Which has higher earnings & valuation, GNTA or IMMP?

Genenta Science has higher earnings, but lower revenue than Prima BioMed. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Genenta Science N/A N/A -$7.39M N/A N/A Prima BioMed $6.69M 8.92 -$39.78M N/A N/A

Is GNTA or IMMP more profitable?

Company Net Margins Return on Equity Return on Assets Genenta Science N/A N/A N/A Prima BioMed N/A N/A N/A

Do analysts rate GNTA or MNOV?

MediciNova has a consensus price target of $7.50, suggesting a potential upside of 467.62%. Given MediciNova's stronger consensus rating and higher probable upside, analysts clearly believe MediciNova is more favorable than Genenta Science. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Genenta Science 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 MediciNova 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 2 Strong Buy rating(s) 2.86

Which has better valuation & earnings, GNTA or MNOV?

Genenta Science has higher earnings, but lower revenue than MediciNova. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Genenta Science N/A N/A -$7.39M N/A N/A MediciNova $596.64K 109.00 -$12M -$0.23 N/A

Do analysts prefer GNTA or PMVP?

PMV Pharmaceuticals has a consensus target price of $5.00, indicating a potential upside of 329.18%. Given PMV Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe PMV Pharmaceuticals is more favorable than Genenta Science. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Genenta Science 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 PMV Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.67

Which has preferable earnings & valuation, GNTA or PMVP?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Genenta Science N/A N/A -$7.39M N/A N/A PMV Pharmaceuticals N/A N/A -$77.74M -$1.49 N/A

Is GNTA or PMVP more profitable?

Genenta Science's return on equity of 0.00% beat PMV Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Genenta Science N/A N/A N/A PMV Pharmaceuticals N/A -68.98% -62.70%

Do analysts recommend IMA or GNTA?

ImageneBio presently has a consensus price target of $26.50, indicating a potential upside of 392.57%. Given ImageneBio's stronger consensus rating and higher possible upside, equities research analysts plainly believe ImageneBio is more favorable than Genenta Science. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ImageneBio 2 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.00 Genenta Science 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings & valuation, IMA or GNTA?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ImageneBio N/A N/A -$45.35M -$5.79 N/A Genenta Science N/A N/A -$7.39M N/A N/A

Is IMA or GNTA more profitable?

Genenta Science's return on equity of 0.00% beat ImageneBio's return on equity. Company Net Margins Return on Equity Return on Assets ImageneBio N/A -38.96% -34.60% Genenta Science N/A N/A N/A

Do analysts prefer IZTC or GNTA?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Invizyne Technologies 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Genenta Science 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings and valuation, IZTC or GNTA?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Invizyne Technologies N/A N/A N/A N/A N/A Genenta Science N/A N/A -$7.39M N/A N/A

Is IZTC or GNTA more profitable?

Company Net Margins Return on Equity Return on Assets Invizyne Technologies N/A N/A N/A Genenta Science N/A N/A N/A

Genenta Science (GNTA) Competitors

$2.24 +0.04 (+1.82%)

As of 11:16 AM Eastern

Compare

GNTA vs. IMMP, MNOV, PMVP, IMA, and IZTC

Should you buy Genenta Science stock or one of its competitors? MarketBeat compares Genenta Science with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Genenta Science include Prima BioMed (IMMP), MediciNova (MNOV), PMV Pharmaceuticals (PMVP), ImageneBio (IMA), and Invizyne Technologies (IZTC). These companies are all part of the "pharmaceutical products" industry.

How does Genenta Science compare to Prima BioMed?

Genenta Science (NASDAQ:GNTA) and Prima BioMed (NASDAQ:IMMP) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, valuation, dividends, profitability, institutional ownership, media sentiment, earnings and analyst recommendations.

In the previous week, Prima BioMed had 19 more articles in the media than Genenta Science. MarketBeat recorded 21 mentions for Prima BioMed and 2 mentions for Genenta Science. Genenta Science's average media sentiment score of 1.43 beat Prima BioMed's score of 0.12 indicating that Genenta Science is being referred to more favorably in the media.

Company	Overall Sentiment
Genenta Science	Positive
Prima BioMed	Neutral

Company	Net Margins	Return on Equity	Return on Assets
Genenta Science	N/A	N/A	N/A
Prima BioMed	N/A	N/A	N/A

Genenta Science has a beta of 0.9, meaning that its share price is 10% less volatile than the broader market. Comparatively, Prima BioMed has a beta of 2.21, meaning that its share price is 121% more volatile than the broader market.

15.1% of Genenta Science shares are owned by institutional investors. Comparatively, 2.3% of Prima BioMed shares are owned by institutional investors. 29.0% of Genenta Science shares are owned by company insiders. Comparatively, 3.1% of Prima BioMed shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Genenta Science has higher earnings, but lower revenue than Prima BioMed.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genenta Science	N/A	N/A	-$7.39M	N/A	N/A
Prima BioMed	$6.69M	8.92	-$39.78M	N/A	N/A

Prima BioMed has a consensus target price of $5.50, indicating a potential upside of 1,257.69%. Given Prima BioMed's stronger consensus rating and higher possible upside, analysts plainly believe Prima BioMed is more favorable than Genenta Science.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genenta Science	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Prima BioMed	1 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.75

Summary

Prima BioMed beats Genenta Science on 5 of the 9 factors compared between the two stocks.

How does Genenta Science compare to MediciNova?

Genenta Science (NASDAQ:GNTA) and MediciNova (NASDAQ:MNOV) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, profitability, risk, analyst recommendations, media sentiment, institutional ownership, dividends and earnings.

Genenta Science has a beta of 0.9, suggesting that its share price is 10% less volatile than the broader market. Comparatively, MediciNova has a beta of 0.62, suggesting that its share price is 38% less volatile than the broader market.

MediciNova has a consensus price target of $7.50, suggesting a potential upside of 467.62%. Given MediciNova's stronger consensus rating and higher probable upside, analysts clearly believe MediciNova is more favorable than Genenta Science.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genenta Science	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
MediciNova	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	2.86

In the previous week, Genenta Science had 1 more articles in the media than MediciNova. MarketBeat recorded 2 mentions for Genenta Science and 1 mentions for MediciNova. Genenta Science's average media sentiment score of 1.43 beat MediciNova's score of 0.97 indicating that Genenta Science is being referred to more favorably in the media.

Company	Overall Sentiment
Genenta Science	Positive
MediciNova	Positive

Genenta Science has higher earnings, but lower revenue than MediciNova.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genenta Science	N/A	N/A	-$7.39M	N/A	N/A
MediciNova	$596.64K	109.00	-$12M	-$0.23	N/A

15.1% of Genenta Science shares are held by institutional investors. Comparatively, 9.9% of MediciNova shares are held by institutional investors. 29.0% of Genenta Science shares are held by company insiders. Comparatively, 14.0% of MediciNova shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Genenta Science has a net margin of 0.00% compared to MediciNova's net margin of -1,962.98%. Genenta Science's return on equity of 0.00% beat MediciNova's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genenta Science	N/A	N/A	N/A
MediciNova	-1,962.98%	-27.28%	-25.24%

Summary

Genenta Science beats MediciNova on 9 of the 14 factors compared between the two stocks.

How does Genenta Science compare to PMV Pharmaceuticals?

Genenta Science (NASDAQ:GNTA) and PMV Pharmaceuticals (NASDAQ:PMVP) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, media sentiment, valuation, institutional ownership, risk, profitability, analyst recommendations and dividends.

15.1% of Genenta Science shares are owned by institutional investors. Comparatively, 90.2% of PMV Pharmaceuticals shares are owned by institutional investors. 29.0% of Genenta Science shares are owned by company insiders. Comparatively, 7.6% of PMV Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Genenta Science had 1 more articles in the media than PMV Pharmaceuticals. MarketBeat recorded 2 mentions for Genenta Science and 1 mentions for PMV Pharmaceuticals. PMV Pharmaceuticals' average media sentiment score of 1.80 beat Genenta Science's score of 1.43 indicating that PMV Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Genenta Science	Positive
PMV Pharmaceuticals	Very Positive

Genenta Science has a beta of 0.9, indicating that its share price is 10% less volatile than the broader market. Comparatively, PMV Pharmaceuticals has a beta of 1.36, indicating that its share price is 36% more volatile than the broader market.

PMV Pharmaceuticals has a consensus target price of $5.00, indicating a potential upside of 329.18%. Given PMV Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe PMV Pharmaceuticals is more favorable than Genenta Science.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genenta Science	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
PMV Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

Genenta Science's return on equity of 0.00% beat PMV Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genenta Science	N/A	N/A	N/A
PMV Pharmaceuticals	N/A	-68.98%	-62.70%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genenta Science	N/A	N/A	-$7.39M	N/A	N/A
PMV Pharmaceuticals	N/A	N/A	-$77.74M	-$1.49	N/A

Summary

PMV Pharmaceuticals beats Genenta Science on 7 of the 12 factors compared between the two stocks.

How does Genenta Science compare to ImageneBio?

ImageneBio (NASDAQ:IMA) and Genenta Science (NASDAQ:GNTA) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, profitability, media sentiment, institutional ownership, risk, analyst recommendations, earnings and valuation.

Genenta Science's return on equity of 0.00% beat ImageneBio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ImageneBio	N/A	-38.96%	-34.60%
Genenta Science	N/A	N/A	N/A

ImageneBio has a beta of 0.72, meaning that its share price is 28% less volatile than the broader market. Comparatively, Genenta Science has a beta of 0.9, meaning that its share price is 10% less volatile than the broader market.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImageneBio	N/A	N/A	-$45.35M	-$5.79	N/A
Genenta Science	N/A	N/A	-$7.39M	N/A	N/A

ImageneBio presently has a consensus price target of $26.50, indicating a potential upside of 392.57%. Given ImageneBio's stronger consensus rating and higher possible upside, equities research analysts plainly believe ImageneBio is more favorable than Genenta Science.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImageneBio	2 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.00
Genenta Science	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

75.0% of ImageneBio shares are held by institutional investors. Comparatively, 15.1% of Genenta Science shares are held by institutional investors. 5.9% of ImageneBio shares are held by company insiders. Comparatively, 29.0% of Genenta Science shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, ImageneBio and ImageneBio both had 2 articles in the media. Genenta Science's average media sentiment score of 1.43 beat ImageneBio's score of 0.94 indicating that Genenta Science is being referred to more favorably in the news media.

Company	Overall Sentiment
ImageneBio	Positive
Genenta Science	Positive

Summary

Genenta Science beats ImageneBio on 6 of the 10 factors compared between the two stocks.

How does Genenta Science compare to Invizyne Technologies?

Invizyne Technologies (NASDAQ:IZTC) and Genenta Science (NASDAQ:GNTA) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, earnings, risk, media sentiment, institutional ownership, profitability, analyst recommendations and valuation.

In the previous week, Genenta Science had 2 more articles in the media than Invizyne Technologies. MarketBeat recorded 2 mentions for Genenta Science and 0 mentions for Invizyne Technologies. Genenta Science's average media sentiment score of 1.43 beat Invizyne Technologies' score of 0.75 indicating that Genenta Science is being referred to more favorably in the news media.

Company	Overall Sentiment
Invizyne Technologies	Positive
Genenta Science	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Invizyne Technologies	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Genenta Science	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Company	Net Margins	Return on Equity	Return on Assets
Invizyne Technologies	N/A	N/A	N/A
Genenta Science	N/A	N/A	N/A

15.1% of Genenta Science shares are owned by institutional investors. 29.0% of Genenta Science shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Invizyne Technologies	N/A	N/A	N/A	N/A	N/A
Genenta Science	N/A	N/A	-$7.39M	N/A	N/A

Summary

Genenta Science beats Invizyne Technologies on 5 of the 5 factors compared between the two stocks.

Get Genenta Science News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GNTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GNTA vs. The Competition

Export

Metric	Genenta Science	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$52.84M	$3.24B	$6.25B	$12.49B
Dividend Yield	N/A	2.33%	2.69%	5.30%
P/E Ratio	N/A	17.70	21.07	24.34
Price / Sales	N/A	324.41	556.32	125.86
Price / Cash	N/A	116.27	42.31	57.88
Price / Book	1.74	6.56	9.78	6.76
Net Income	-$7.39M	$24.15M	$3.56B	$337.09M
7 Day Performance	173.00%	-0.45%	-0.18%	1.50%
1 Month Performance	206.85%	3.09%	4.95%	6.18%
1 Year Performance	-48.51%	49.58%	28.44%	35.62%

Genenta Science Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GNTA Genenta Science	1.1468 of 5 stars	$2.24 +1.8%	N/A	-51.0%	$52.84M	N/A	N/A	7	Positive News Short Interest Decrease
IMMP Prima BioMed	2.6934 of 5 stars	$0.45 -1.9%	$5.50 +1,136.0%	-77.6%	$65.58M	$4.08M	N/A	2,021
MNOV MediciNova	3.5075 of 5 stars	$1.32 -3.6%	$7.50 +467.8%	-5.0%	$65.07M	$410K	N/A	10
PMVP PMV Pharmaceuticals	2.9796 of 5 stars	$1.22 -1.2%	$5.00 +311.5%	+34.5%	$64.80M	N/A	N/A	50	News Coverage
IMA ImageneBio	3.036 of 5 stars	$5.82 +0.0%	$26.50 +355.2%	-64.5%	$62.00M	$800K	N/A	70

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GNTA) was last updated on 6/3/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Genenta Science (GNTA) Competitors

GNTA vs. IMMP, MNOV, PMVP, IMA, and IZTC

How does Genenta Science compare to Prima BioMed?

Summary

How does Genenta Science compare to MediciNova?

Summary

How does Genenta Science compare to PMV Pharmaceuticals?

Summary

How does Genenta Science compare to ImageneBio?

Summary

How does Genenta Science compare to Invizyne Technologies?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GNTA vs. The Competition

Genenta Science Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Genenta Science (GNTA) Competitors

GNTA vs. IMMP, MNOV, PMVP, IMA, and IZTC

How does Genenta Science compare to Prima BioMed?

Does the media favor GNTA or IMMP?

Is GNTA or IMMP more profitable?

Which has more volatility & risk, GNTA or IMMP?

Do institutionals and insiders believe in GNTA or IMMP?

Which has higher earnings & valuation, GNTA or IMMP?

Do analysts rate GNTA or IMMP?

Summary

How does Genenta Science compare to MediciNova?

Which has more volatility and risk, GNTA or MNOV?

Do analysts rate GNTA or MNOV?

Does the media prefer GNTA or MNOV?

Which has better valuation & earnings, GNTA or MNOV?

Do institutionals & insiders hold more shares of GNTA or MNOV?

Is GNTA or MNOV more profitable?

Summary

How does Genenta Science compare to PMV Pharmaceuticals?

Do insiders & institutionals believe in GNTA or PMVP?

Does the media favor GNTA or PMVP?

Which has more risk and volatility, GNTA or PMVP?

Do analysts prefer GNTA or PMVP?

Is GNTA or PMVP more profitable?

Which has preferable earnings & valuation, GNTA or PMVP?

Summary

How does Genenta Science compare to ImageneBio?

Is IMA or GNTA more profitable?

Which has more volatility & risk, IMA or GNTA?

Which has better earnings & valuation, IMA or GNTA?

Do analysts recommend IMA or GNTA?

Do institutionals and insiders believe in IMA or GNTA?

Does the media refer more to IMA or GNTA?

Summary

How does Genenta Science compare to Invizyne Technologies?

Does the media refer more to IZTC or GNTA?

Do analysts prefer IZTC or GNTA?

Is IZTC or GNTA more profitable?

Do institutionals & insiders believe in IZTC or GNTA?

Which has better earnings and valuation, IZTC or GNTA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GNTA vs. The Competition

Genenta Science Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools